UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

European journal of pharmacology, 2008-04, Vol.584 (1), p.118-124

2008

Volltextzugriff (PDF)

Fat Intake Affects Adiposity, Comorbidity Factors, and Energy Metabolism of Sprague-Dawley Rats

Obesity (Silver Spring, Md.), 2002-09, Vol.10 (9), p.956-963

2002

Volltextzugriff (PDF)

Antidiabetic Properties of the Histamine H3 Receptor Protean Agonist Proxyfan

Endocrinology (Philadelphia), 2011-03, Vol.152 (3), p.828-835

2011

Volltextzugriff (PDF)

Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors

Obesity (Silver Spring, Md.), 2005-01, Vol.13 (1), p.36-47

2005

Volltextzugriff (PDF)

Ultra-performance hydrophilic interaction LC-MS/MS for the determination of metformin in mouse plasma

Bioanalysis, 2009-09, Vol.1 (6), p.1073-1079

2009

Volltextzugriff (PDF)

Identification and characterization of sebaceous gland atrophy-sparing DGAT1 inhibitors

PloS one, 2014-02, Vol.9 (2), p.e88908

2014

Volltextzugriff (PDF)

Central melanocortin system modulates energy intake and expenditure of obese and lean Zucker rats

American journal of physiology. Regulatory, integrative and comparative physiology, 2001-08, Vol.281 (2), p.444-R451

2001

Volltextzugriff (PDF)

Identification of Potent and Selective Neuropeptide Y Y1 Receptor Agonists with Orexigenic Activity in Vivo

Molecular pharmacology, 2001-09, Vol.60 (3), p.534

2001

Volltextzugriff (PDF)

Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms

American journal of physiology: endocrinology and metabolism, 2004-10, Vol.287 (4), p.E706-E711

2004

Volltextzugriff (PDF)

Activation of the NPY Y5 receptor regulates both feeding and energy expenditure

American journal of physiology. Regulatory, integrative and comparative physiology, 1999-11, Vol.277 (5), p.1428-R1434

1999

Volltextzugriff (PDF)

Characterization of diet-induced obese rats that develop persistent obesity after 6 months of high-fat followed by 1 month of low-fat diet

Brain research, 2002-05, Vol.936 (1), p.87-90

2002

Volltextzugriff (PDF)

Evidence for the Presence of a Proteinase-Activated Receptor Distinct From the Thrombin Receptor in Vascular Endothelial Cells

Circulation research, 1996-04, Vol.78 (4), p.581-588

1996

Volltextzugriff (PDF)

Discovery of novel orally active ureido NPY Y5 receptor antagonists

Bioorganic & medicinal chemistry, 2008-02, Vol.18 (3), p.1146-1150

2008

Volltextzugriff (PDF)

[D-Trp34] neuropeptide Y is a potent and selective neuropeptide Y Y5 receptor agonist with dramatic effects on food intake

Peptides (New York, N.Y. : 1980), 2000-03, Vol.21 (3), p.393-399

2000

Volltextzugriff (PDF)

SGLT Inhibitors Enhance Endogenous Glucose Productions (EGP) in a Preclinical Animal Model

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

The GalR2 galanin receptor mediates galanin-induced jejunal contraction, but not feeding behavior, in the rat: differentiation of central and peripheral effects of receptor subtype activation

FEBS letters, 1998-09, Vol.434 (3), p.277-282

1998

Volltextzugriff (PDF)

Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance

Diabetes (New York, N.Y.), 2014-01, Vol.63 (1), p.300-311

2014

Volltextzugriff (PDF)

Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus

American journal of physiology: endocrinology and metabolism, 2016-12, Vol.311 (6), p.E911-E921

2016

Volltextzugriff (PDF)

Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP‑4 Inhibitors for the Treatment of Type 2 Diabetes

ACS medicinal chemistry letters, 2016-05, Vol.7 (5), p.498-501

2016

Volltextzugriff (PDF)

Development of Novel Benzomorpholine Class of Diacylglycerol Acyltransferase I Inhibitors

ACS medicinal chemistry letters, 2014-05, Vol.5 (5), p.544-549

2014

Volltextzugriff (PDF)

Synthesis and structure–activity relationships of 2-(1,4′-bipiperidin-1′-yl)thiazolopyridine as H 3 receptor antagonists

Bioorganic & medicinal chemistry letters, 2009-11, Vol.19 (21), p.6176-6180

2009

Volltextzugriff (PDF)

Novel molecular targets for the treatment of obesity

Drug discovery today, 1998-06, Vol.3 (6), p.250-256

1998

Volltextzugriff (PDF)

The Discovery of N‑((2H‑Tetrazol-5-yl)methyl)-4-((R)‑1-((5r,8R)‑8‑(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): A Potent and Selective Glucagon Receptor Antagonist

Journal of medicinal chemistry, 2014-03, Vol.57 (6), p.2601-2610

2014

Volltextzugriff (PDF)

Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1)

Bioorganic & medicinal chemistry letters, 2013-02, Vol.23 (3), p.791-796

2013

Volltextzugriff (PDF)

Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity

Bioorganic & medicinal chemistry letters, 2013-11, Vol.23 (21), p.6004-6009

2013

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(79)

Publikationsform

Sprache

Englisch
(85)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

Fat Intake Affects Adiposity, Comorbidity Factors, and Energy Metabolism of Sprague-Dawley Rats

Antidiabetic Properties of the Histamine H3 Receptor Protean Agonist Proxyfan

Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors

Ultra-performance hydrophilic interaction LC-MS/MS for the determination of metformin in mouse plasma

Identification and characterization of sebaceous gland atrophy-sparing DGAT1 inhibitors

Central melanocortin system modulates energy intake and expenditure of obese and lean Zucker rats

Identification of Potent and Selective Neuropeptide Y Y1 Receptor Agonists with Orexigenic Activity in Vivo

Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms

Activation of the NPY Y5 receptor regulates both feeding and energy expenditure

Characterization of diet-induced obese rats that develop persistent obesity after 6 months of high-fat followed by 1 month of low-fat diet

Evidence for the Presence of a Proteinase-Activated Receptor Distinct From the Thrombin Receptor in Vascular Endothelial Cells

Discovery of novel orally active ureido NPY Y5 receptor antagonists

[D-Trp34] neuropeptide Y is a potent and selective neuropeptide Y Y5 receptor agonist with dramatic effects on food intake

SGLT Inhibitors Enhance Endogenous Glucose Productions (EGP) in a Preclinical Animal Model

The GalR2 galanin receptor mediates galanin-induced jejunal contraction, but not feeding behavior, in the rat: differentiation of central and peripheral effects of receptor subtype activation

Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance

Quantifying rates of glucose production in vivo following an intraperitoneal tracer bolus

Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP‑4 Inhibitors for the Treatment of Type 2 Diabetes

Development of Novel Benzomorpholine Class of Diacylglycerol Acyltransferase I Inhibitors

Synthesis and structure–activity relationships of 2-(1,4′-bipiperidin-1′-yl)thiazolopyridine as H 3 receptor antagonists

Novel molecular targets for the treatment of obesity

The Discovery of N‑((2H‑Tetrazol-5-yl)methyl)-4-((R)‑1-((5r,8R)‑8‑(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): A Potent and Selective Glucagon Receptor Antagonist

Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1)

Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity

Suchergebnisse filtern